CN104892755B - 百日咳prn 蛋白单克隆抗体及其应用 - Google Patents
百日咳prn 蛋白单克隆抗体及其应用 Download PDFInfo
- Publication number
- CN104892755B CN104892755B CN201510161318.2A CN201510161318A CN104892755B CN 104892755 B CN104892755 B CN 104892755B CN 201510161318 A CN201510161318 A CN 201510161318A CN 104892755 B CN104892755 B CN 104892755B
- Authority
- CN
- China
- Prior art keywords
- pertussis
- monoclonal antibody
- seq
- amino acid
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000005702 Pertussis Diseases 0.000 title claims abstract description 38
- 238000001514 detection method Methods 0.000 claims abstract description 17
- 229940066827 pertussis vaccine Drugs 0.000 claims abstract description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 11
- 210000004408 hybridoma Anatomy 0.000 claims description 22
- 238000002965 ELISA Methods 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000000090 biomarker Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 238000007689 inspection Methods 0.000 claims description 2
- 238000002372 labelling Methods 0.000 claims description 2
- 239000000427 antigen Substances 0.000 abstract description 6
- 102000036639 antigens Human genes 0.000 abstract description 6
- 108091007433 antigens Proteins 0.000 abstract description 6
- 241000894006 Bacteria Species 0.000 abstract description 5
- 229960005486 vaccine Drugs 0.000 abstract description 5
- 241000193830 Bacillus <bacterium> Species 0.000 abstract description 4
- 230000001717 pathogenic effect Effects 0.000 abstract description 4
- 244000052769 pathogen Species 0.000 abstract description 3
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 2
- 208000026935 allergic disease Diseases 0.000 abstract description 2
- 230000009610 hypersensitivity Effects 0.000 abstract description 2
- 108010021711 pertactin Proteins 0.000 description 27
- 108010081690 Pertussis Toxin Proteins 0.000 description 15
- 238000000034 method Methods 0.000 description 11
- 101710154643 Filamentous hemagglutinin Proteins 0.000 description 8
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 241000588832 Bordetella pertussis Species 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000000304 virulence factor Substances 0.000 description 3
- 230000007923 virulence factor Effects 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 229940032024 DPT vaccine Drugs 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
- 229940124832 acellular pertussis vaccine Drugs 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000009668 clonal growth Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003181 encephalopathic effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 1
- 229940124856 vaccine component Drugs 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510161318.2A CN104892755B (zh) | 2014-04-08 | 2015-04-07 | 百日咳prn 蛋白单克隆抗体及其应用 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2014101394797 | 2014-04-08 | ||
CN201410139479 | 2014-04-08 | ||
CN201510161318.2A CN104892755B (zh) | 2014-04-08 | 2015-04-07 | 百日咳prn 蛋白单克隆抗体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104892755A CN104892755A (zh) | 2015-09-09 |
CN104892755B true CN104892755B (zh) | 2018-02-16 |
Family
ID=54025762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510161318.2A Active CN104892755B (zh) | 2014-04-08 | 2015-04-07 | 百日咳prn 蛋白单克隆抗体及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104892755B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106117357B (zh) * | 2016-06-29 | 2019-08-30 | 烟台正海生物科技股份有限公司 | Bmp-2抗体及其在检测骨修复材料中bmp-2蛋白含量中的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0209493A2 (en) * | 1985-07-16 | 1987-01-21 | Ciba-Geigy Ag | Prophylaxis and treatment of whooping cough |
CN1216065A (zh) * | 1996-03-15 | 1999-05-05 | 柏林马普科技促进协会 | 重组蛋白的运出系统 |
WO2000064457A1 (en) * | 1999-04-23 | 2000-11-02 | Dalhousie University | Genetically engineered oral commensal organisms as vaccines |
CN101074442A (zh) * | 2007-04-29 | 2007-11-21 | 中国药品生物制品检定所 | 百日咳疫苗保护性抗原的重组表达及其应用 |
CN101280016A (zh) * | 2008-05-27 | 2008-10-08 | 中国人民解放军第二军医大学 | 可卡因-苯丙胺调节转录肽单链抗体及其应用 |
-
2015
- 2015-04-07 CN CN201510161318.2A patent/CN104892755B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0209493A2 (en) * | 1985-07-16 | 1987-01-21 | Ciba-Geigy Ag | Prophylaxis and treatment of whooping cough |
CN1216065A (zh) * | 1996-03-15 | 1999-05-05 | 柏林马普科技促进协会 | 重组蛋白的运出系统 |
WO2000064457A1 (en) * | 1999-04-23 | 2000-11-02 | Dalhousie University | Genetically engineered oral commensal organisms as vaccines |
CN101074442A (zh) * | 2007-04-29 | 2007-11-21 | 中国药品生物制品检定所 | 百日咳疫苗保护性抗原的重组表达及其应用 |
CN101280016A (zh) * | 2008-05-27 | 2008-10-08 | 中国人民解放军第二军医大学 | 可卡因-苯丙胺调节转录肽单链抗体及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104892755A (zh) | 2015-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1280828B1 (en) | Anthrax-specific antigen, vaccines comprising said antigen, anthrax-specific antibodies, and their uses | |
CN105087497B (zh) | 杂交瘤细胞株zjeb8-01、抗埃博拉病毒gp蛋白单克隆抗体及其制备和应用 | |
CN101313216A (zh) | 酵母突变体中产生的糖基化多肽及其使用方法 | |
CN104862283B (zh) | 一对高特异性高亲和力结合人肌红蛋白的单克隆抗体及其应用 | |
CN105294843B (zh) | 肠道病毒71型vp1抗原的免疫原性多肽及其制备方法与应用 | |
CN112175071A (zh) | 一种新型冠状病毒刺突蛋白单克隆抗体的制备方法 | |
CN103642792A (zh) | 一种抗丙肝病毒的中和性单克隆抗体的制备及其应用 | |
CN104892755B (zh) | 百日咳prn 蛋白单克隆抗体及其应用 | |
CN103254312A (zh) | 一种鼠源单克隆抗体及其制备方法和用途 | |
CN101580545B (zh) | 抗h5n1来源的血凝素蛋白的单克隆抗体及其应用 | |
CN103923882B (zh) | 甲肝病毒单克隆抗体及其应用 | |
CN101921337B (zh) | 间日疟原虫乳酸脱氢酶抗体、相关制备方法、杂交瘤细胞株和应用 | |
CN104829711A (zh) | 脑膜炎球菌荚膜多糖单克隆抗体及其应用 | |
CN101781656A (zh) | 齿兰环斑病毒外壳蛋白基因的表达及其抗体制备方法 | |
CN105158475B (zh) | 用于检测转基因农作物的单克隆抗体对及双抗夹心酶联免疫检测试剂盒 | |
CN105658661A (zh) | 疫苗 | |
CN103923881A (zh) | 甲肝病毒单克隆抗体及其应用 | |
Li et al. | Production of mouse monoclonal antibodies against Helicobacter pylori Lpp20 and mapping the antigenic epitope by phage display library | |
CN105504051A (zh) | 狂犬病毒核蛋白单克隆抗体及其应用 | |
CN103214571B (zh) | 一种鼠源单克隆抗体及其制备方法和用途 | |
CN113929772B (zh) | SARS-CoV-2中和抗体及其制备方法与应用 | |
CN109666071A (zh) | 一种巴氏杆菌蛋白的多克隆抗体及单克隆抗体的制备 | |
CN105445460B (zh) | 一种抗乙肝病毒HBx单克隆抗体及其制备与应用 | |
Falklind-Jerkérus et al. | Peptides mimicking Vibrio cholerae O139 capsular polysaccharide elicit protective antibody response | |
CN105039260A (zh) | 白喉类毒素单克隆抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200428 Address after: 101111 2-201, building 18, No. 99, Kechuang 14th Street, economic and Technological Development Zone, Daxing District, Beijing Patentee after: ABMAX BIOTECHNOLOGY Co.,Ltd. Address before: Section 14 economic and Technological Development Zone of Beijing City, No. 99 18-2-201 street 101111 Patentee before: ABMAX BIOPHARMACEUTICALS |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231027 Address after: Tianjin International Biomedical Joint Research Institute Experimental Building S1101, No. 220 Dongting Road, Binhai New Area, Tianjin, 300457 Patentee after: Beijing Tiancheng Biotechnology (Tianjin) Co.,Ltd. Address before: Room 2-201, Building 18, No. 99 Kechuang 14th Street, Daxing District Economic and Technological Development Zone, Beijing, 101111 Patentee before: ABMAX BIOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right |